tradingkey.logo

Nautilus Biotechnology Inc

NAUT
View Detailed Chart
1.510USD
0.000
Close 11/06, 16:00ETQuotes delayed by 15 min
190.72MMarket Cap
LossP/E TTM

Nautilus Biotechnology Inc

1.510
0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

+7.09%

1 Month

+74.55%

6 Months

+126.08%

Year to Date

-10.12%

1 Year

-47.75%

View Detailed Chart

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nautilus Biotechnology Inc's Score

Industry at a Glance

Industry Ranking
210 / 501
Overall Ranking
370 / 4682
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Strong Buy
Current Rating
2.500
Target Price
+65.56%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nautilus Biotechnology Inc Highlights

StrengthsRisks
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -2.59, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 57.12M shares, decreasing 6.05% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 619.91K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.45.

Nautilus Biotechnology Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Nautilus Biotechnology Inc Info

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Ticker SymbolNAUT
CompanyNautilus Biotechnology Inc
CEOMr. Sujal Patel
Websitehttps://www.nautilus.bio/
KeyAI